Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
J Exp Med ; 200(7): 587-99, 2004 Oct 04.
Artículo en Inglés | MEDLINE | ID: mdl-15508184

RESUMEN

Human immunodeficiency virus (HIV) infection leads to numerous perturbations of B cells through mechanisms that remain elusive. We performed DNA microarray, phenotypic, and functional analyses in an effort to elucidate mechanisms of B cell perturbation associated with ongoing HIV replication. 42 genes were up-regulated in B cells of HIV-viremic patients when compared with HIV-aviremic and HIV-negative patients, the majority of which were interferon (IFN)-stimulated or associated with terminal differentiation. Flow cytometry confirmed these increases and indicated that CD21(low) B cells, enhanced in HIV-viremic patients, were largely responsible for the changes. Increased expression of the tumor necrosis factor (TNF) superfamily (TNFSF) receptor CD95 correlated with increased susceptibility to CD95-mediated apoptosis of CD21(low) B cells, which, in turn, correlated with HIV plasma viremia. Increased expression of BCMA, a weak TNFSF receptor for B lymphocyte stimulator (BLyS), on CD21(low) B cells was associated with a concomitant reduction in the expression of the more potent BLyS receptor, BAFF-R, that resulted in reduced BLyS binding and BLyS-mediated survival. These findings demonstrate that altered expression of genes associated with IFN stimulation and terminal differentiation in B cells of HIV-viremic patients lead to an increased propensity to cell death, which may have substantial deleterious effects on B cell responsiveness to antigenic stimulation.


Asunto(s)
Apoptosis/inmunología , Linfocitos B/metabolismo , Linfocitos B/virología , Infecciones por VIH/inmunología , Receptores del Factor de Necrosis Tumoral/metabolismo , Regulación hacia Arriba , Receptor del Factor Activador de Células B , Antígeno de Maduración de Linfocitos B , Linfocitos B/inmunología , Diferenciación Celular/inmunología , Membrana Celular/metabolismo , Citometría de Flujo , Perfilación de la Expresión Génica , Infecciones por VIH/sangre , Humanos , Interferones/metabolismo , Proteínas de la Membrana/metabolismo , Análisis de Secuencia por Matrices de Oligonucleótidos , Fenotipo , Receptores de Complemento 3d/metabolismo , Receptor fas/biosíntesis
2.
J Exp Med ; 200(5): 587-99, 2004 Sep 06.
Artículo en Inglés | MEDLINE | ID: mdl-15353552

RESUMEN

Human immunodeficiency virus (HIV) infection leads to numerous perturbations of B cells through mechanisms that remain elusive. We performed DNA microarray, phenotypic, and functional analyses in an effort to elucidate mechanisms of B cell perturbation associated with ongoing HIV replication. 42 genes were up-regulated in B cells of HIV-viremic patients when compared with HIV-aviremic and HIV-negative patients, the majority of which were interferon (IFN)-stimulated or associated with terminal differentiation. Flow cytometry confirmed these increases and indicated that CD21(low) B cells, enhanced in HIV-viremic patients, were largely responsible for the changes. Increased expression of the tumor necrosis factor (TNF) superfamily (TNFSF) receptor CD95 correlated with increased susceptibility to CD95-mediated apoptosis of CD21(low) B cells, which, in turn, correlated with HIV plasma viremia. Increased expression of BCMA, a weak TNFSF receptor for B lymphocyte stimulator (BLyS), on CD21(low) B cells was associated with a concomitant reduction in the expression of the more potent BLyS receptor, BAFF-R, that resulted in reduced BLyS binding and BLyS-mediated survival. These findings demonstrate that altered expression of genes associated with IFN stimulation and terminal differentiation in B cells of HIV-viremic patients lead to an increased propensity to cell death, which may have substantial deleterious effects on B cell responsiveness to antigenic stimulation.


Asunto(s)
Linfocitos B/citología , Linfocitos B/virología , Infecciones por VIH/sangre , Seropositividad para VIH , ADP-Ribosil Ciclasa/biosíntesis , ADP-Ribosil Ciclasa 1 , Antígenos CD/biosíntesis , Apoptosis , Linfocitos B/patología , Diferenciación Celular , Membrana Celular/metabolismo , Separación Celular , Citometría de Flujo , Humanos , Interferones/metabolismo , Glicoproteínas de Membrana , Análisis de Secuencia por Matrices de Oligonucleótidos , Fenotipo , Receptores de Complemento 3d/biosíntesis , Regulación hacia Arriba , Receptor fas/biosíntesis
3.
Diabetes ; 54(1): 251-8, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15616036

RESUMEN

The primary therapeutic goal for the treatment of diabetes is maintenance of a long-term, near-normoglycemic condition and prevention of the onset or progression of the complications associated with the disease. Although several analogs of human insulin have been developed, the currently prescribed long-acting insulin analogs do not provide a stable basal glycemia for more than a few hours. Here, we report the development of Albulin, a long-acting insulin analog obtained by direct gene fusion of a single-chain human insulin to human serum albumin. Albulin showed an elimination t(1/2) of approximately 7 h in normoglycemic mice. In vitro pharmacodynamic profiles for Albulin characterized by receptor binding, inhibition of gluconeogenesis, induction of glucose uptake, and global regulation of gene expression in relevant cell types showed that Albulin produced similar activity profiles compared with that of recombinant human insulin. A single Albulin administration in vivo normalized blood glucose level in diabetic mice in a relatively peakless and sustained (24-h) fashion. A further reduction in glucose levels was achieved by administering a recombinant human insulin a few hours after Albulin injection in mice, indicating the potential for Albulin therapy in combination with available fast-acting insulin derivatives. In summary, Albulin displays characteristics of a potent long-acting insulin analog that can be evaluated for use as a novel insulin therapy for patients with insulin-dependent diabetes.


Asunto(s)
Insulina/genética , Insulina/farmacocinética , Proteínas Recombinantes de Fusión/farmacocinética , Albúmina Sérica/genética , Albúmina Sérica/farmacocinética , Células 3T3 , Adipocitos/efectos de los fármacos , Adipocitos/metabolismo , Animales , Clonación Molecular , Escherichia coli , Perfilación de la Expresión Génica , Regulación de la Expresión Génica/efectos de los fármacos , Genes Sintéticos , Glucosa/metabolismo , Humanos , Insulina/farmacología , Insulina de Acción Prolongada , Insulina Regular Humana , Masculino , Ratones , Ratones Endogámicos C57BL , Reacción en Cadena de la Polimerasa , Receptor de Insulina/metabolismo , Proteínas Recombinantes de Fusión/farmacología , Albúmina Sérica/farmacología , Albúmina Sérica Humana
4.
J Interferon Cytokine Res ; 23(1): 25-36, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12639296

RESUMEN

The long half-life and stability of human serum albumin (HSA) make it an attractive candidate for fusion to short-lived therapeutic proteins. Albuferon (Human Genome Sciences [HGS], Inc., Rockville, MD) beta is a novel recombinant protein derived from a gene fusion of interferon-beta (IFN-beta ) and HSA. In vitro, Albuferon beta displays antiviral and antiproliferative activities and triggers the IFN-stimulated response element (ISRE) signal transduction pathway. Array analysis of 5694 independent genes in Daudi-treated cells revealed that Albuferon beta and IFN-beta induce the expression of an identical set of 30 genes, including 9 previously not identified. In rhesus monkeys administered a dose of 50 microg/kg intravenously (i.v.) or subcutaneously (s.c.) or 300 microg/kg s.c., Albuferon beta demonstrated favorable pharmacokinetic properties. Subcutaneous bioavailability was 87%, plasma clearance at 4.7-5.7 ml/h/kg was approximately 140-fold lower than that of IFN-beta, and the terminal half-life was 36-40 h compared with 8 h for IFN-beta. Importantly, Albuferon beta induced sustained increases in serum neopterin levels and 2',5' mRNA expression. At a molar dose equivalent to one-half the dose of IFN-beta, Albuferon beta elicited comparable neopterin responses and significantly higher 2',5'-OAS mRNA levels in rhesus monkeys. The enhanced in vivo pharmacologic properties of IFN-beta when fused to serum albumin suggest a clinical opportunity for improved IFN-beta therapy.


Asunto(s)
Interferón Tipo I/farmacología , Interferón Tipo I/farmacocinética , Albúmina Sérica/farmacología , Albúmina Sérica/farmacocinética , Animales , Antivirales/farmacocinética , Antivirales/farmacología , Secuencia de Bases , División Celular/efectos de los fármacos , Línea Celular , Femenino , Expresión Génica/efectos de los fármacos , Perfilación de la Expresión Génica , Humanos , Técnicas In Vitro , Macaca mulatta , Análisis de Secuencia por Matrices de Oligonucleótidos , ARN Mensajero/genética , ARN Mensajero/metabolismo , Proteínas Recombinantes de Fusión/farmacocinética , Proteínas Recombinantes de Fusión/farmacología , Proteínas Recombinantes , Transducción de Señal/efectos de los fármacos
5.
Cancer J ; 14(3): 133-7, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18536551

RESUMEN

Phase 0 clinical trials, developed in response to the United States Food and Drug Administration (FDA)'s recent exploratory Investigational New Drug (IND) guidance, are intended to expedite the clinical evaluation of new molecular entities. The exploratory IND supports the performance of first-in-human testing of new investigational agents at subtherapeutic doses based on reduced manufacturing and toxicologic requirements, allowing the demonstration of drug-target effects and assessment of pharmacokinetic-pharmacodynamic relationships in humans earlier in clinical development. The objectives of a phase 0 cancer clinical trial are to establish at the very earliest opportunity-before large numbers of patients have been accrued and exposed to potential drug-associated toxicity-whether an agent is modulating its target in a tumor, and consequently whether further clinical development is warranted. We review here the fundamental requirements of clinical studies conducted under an exploratory IND and address some common misconceptions regarding oncologic phase 0 trials.


Asunto(s)
Investigación Biomédica/métodos , Ensayos Clínicos como Asunto , Drogas en Investigación , Investigación Biomédica/legislación & jurisprudencia , Humanos , Farmacocinética , Farmacología , Estados Unidos , United States Food and Drug Administration
6.
Genome Biol ; 4(5): R30, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12734010

RESUMEN

BACKGROUND: A large fraction of the human genome is attributable to L1 retrotransposon sequences. Not only do L1s themselves make up a significant portion of the genome, but L1-encoded proteins are thought to be responsible for the transposition of other repetitive elements and processed pseudogenes. In addition, L1s can mobilize non-L1, 3'-flanking DNA in a process called 3' transduction. Using computational methods, we collected DNA sequences from the human genome for which we have high confidence of their mobilization through L1-mediated 3' transduction. RESULTS: The precursors of L1s with transduced sequence can often be identified, allowing us to reconstruct L1 element families in which a single parent L1 element begot many progeny L1s. Of the L1s exhibiting a sequence structure consistent with 3' transduction (L1 with transduction-derived sequence, L1-TD), the vast majority were located in duplicated regions of the genome and thus did not necessarily represent unique insertion events. Of the remaining L1-TDs, some lack a clear polyadenylation signal, but the alignment between the parent-progeny sequences nevertheless ends in an A-rich tract of DNA. CONCLUSIONS: Sequence data suggest that during the integration into the genome of RNA representing an L1-TD, reverse transcription may be primed internally at A-rich sequences that lie downstream of the L1 3' untranslated region. The occurrence of L1-mediated transduction in the human genome may be less frequent than previously thought, and an accurate estimate is confounded by the frequent occurrence of segmental genomic duplications.


Asunto(s)
ADN/genética , Elementos de Nucleótido Esparcido Largo/genética , Secuencia de Bases , Biología Computacional/métodos , Genoma Humano , Humanos , Datos de Secuencia Molecular , Mutagénesis Insercional , Recombinación Genética , Homología de Secuencia de Ácido Nucleico
7.
Genome Biol ; 3(10): research0052, 2002 Sep 19.
Artículo en Inglés | MEDLINE | ID: mdl-12372140

RESUMEN

BACKGROUND: As the rough draft of the human genome sequence nears a finished product and other genome-sequencing projects accumulate sequence data exponentially, bioinformatics is emerging as an important tool for studies of transposon biology. In particular, L1 elements exhibit a variety of sequence structures after insertion into the human genome that are amenable to computational analysis. We carried out a detailed analysis of the anatomy and distribution of L1 elements in the human genome using a new computer program, TSDfinder, designed to identify transposon boundaries precisely. RESULTS: Structural variants of L1 elements shared similar trends in the length and quality of their target site duplications (TSDs) and poly(A) tails. Furthermore, we found no correlation between the composition and genomic location of the pre-insertion locus and the resulting anatomy of the L1 insertion. We verified that L1 insertions with TSDs have the 5'-TTAAAA-3' cleavage site associated with L1 endonuclease activity. In addition, the second target DNA cut required for L1 insertion weakly matches the consensus pattern TTAAAA. On the other hand, the L1-internal breakpoints of deleted and inverted L1 elements do not resemble L1 endonuclease cleavage sites. Finally, the genome sequence data indicate that whereas singly inverted elements are common, doubly inverted elements are almost never found. CONCLUSIONS: The sequence data give no indication that the creation of L1 structural variants depends on characteristics of the insertion locus. In addition, the formation of 5' truncated and 5' inverted L1s are probably not due to the action of the L1 endonuclease.


Asunto(s)
Genoma Humano , Mutagénesis Insercional/genética , Retroelementos/genética , Algoritmos , Secuencia de Bases , Sitios de Unión/genética , Biología Computacional/métodos , Humanos , Poli A/genética , Recombinación Genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA